Bifendatatum was treated as a positive control for assessing ROF in vivo, as it has previously been proven to be an anti-hepatitis drug via its mechanisms of reducing alanine transaminase secretion (Deng et al., 2020; Xu S. et al., 2021). Here, GPT is linked to hepatitis A virus infection.